240 related articles for article (PubMed ID: 24718888)
21. Novel insight into mutational landscape of head and neck squamous cell carcinoma.
Gaykalova DA; Mambo E; Choudhary A; Houghton J; Buddavarapu K; Sanford T; Darden W; Adai A; Hadd A; Latham G; Danilova LV; Bishop J; Li RJ; Westra WH; Hennessey P; Koch WM; Ochs MF; Califano JA; Sun W
PLoS One; 2014; 9(3):e93102. PubMed ID: 24667986
[TBL] [Abstract][Full Text] [Related]
22. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
23. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
[TBL] [Abstract][Full Text] [Related]
24. Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck.
Nunn J; Nagini S; Risk JM; Prime W; Maloney P; Liloglou T; Jones AS; Rogers SR; Gosney JR; Woolgar J; Field JK
Oral Oncol; 2003 Feb; 39(2):115-29. PubMed ID: 12509964
[TBL] [Abstract][Full Text] [Related]
25. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
Tillman BN; Yanik M; Birkeland AC; Liu CJ; Hovelson DH; Cani AK; Palanisamy N; Carskadon S; Carey TE; Bradford CR; Tomlins SA; McHugh JB; Spector ME; Brenner JCh
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1646-52. PubMed ID: 26849095
[TBL] [Abstract][Full Text] [Related]
27. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.
Giefing M; Wierzbicka M; Szyfter K; Brenner JC; Braakhuis BJ; Brakenhoff RH; Bradford CR; Sorensen JA; Rinaldo A; Rodrigo JP; Takes RP; Ferlito A
Eur J Cancer; 2016 Mar; 55():147-57. PubMed ID: 26851381
[TBL] [Abstract][Full Text] [Related]
28. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
[TBL] [Abstract][Full Text] [Related]
29. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).
Galot R; Machiels JH
Cancer Treat Rev; 2020 Apr; 85():101992. PubMed ID: 32092618
[TBL] [Abstract][Full Text] [Related]
30. Immune profiles in primary squamous cell carcinoma of the head and neck.
Saloura V; Izumchenko E; Zuo Z; Bao R; Korzinkin M; Ozerov I; Zhavoronkov A; Sidransky D; Bedi A; Hoque MO; Koeppen H; Keck MK; Khattri A; London N; Kotlov N; Fatima A; Vougiouklakis T; Nakamura Y; Lingen M; Agrawal N; Savage PA; Kron S; Kline J; Kowanetz M; Seiwert TY
Oral Oncol; 2019 Sep; 96():77-88. PubMed ID: 31422218
[TBL] [Abstract][Full Text] [Related]
31. Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers.
Boldrup L; Coates PJ; Hedberg Y; Sjöström B; Dahlqvist A; Nylander K
Int J Oncol; 2005 Dec; 27(6):1661-7. PubMed ID: 16273222
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
33. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
[TBL] [Abstract][Full Text] [Related]
34. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
[TBL] [Abstract][Full Text] [Related]
35. MiR-1275 promotes cell migration, invasion and proliferation in squamous cell carcinoma of head and neck via up-regulating IGF-1R and CCR7.
Liu MD; Wu H; Wang S; Pang P; Jin S; Sun CF; Liu FY
Gene; 2018 Mar; 646():1-7. PubMed ID: 29278769
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Theurer JA; Stecho W; Yoo J; Kwan K; Wehrli B; Harry V; Black M; Pinto N; Winquist E; Palma D; Richter S; Barrett JW; Danielle MacNeil S; Fung K; Howlett CJ; Nichols AC
Pathol Oncol Res; 2016 Jan; 22(1):35-40. PubMed ID: 26271341
[TBL] [Abstract][Full Text] [Related]
37. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra.
Olshan AF; Weissler MC; Pei H; Conway K
Cancer Epidemiol Biomarkers Prev; 1997 Jul; 6(7):499-504. PubMed ID: 9232336
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of mutations within the TP53 gene in patients with squamous cell carcinoma of the head and neck].
Golusinski P; Lamperska K; Pazdrowski J; Golusinski W
Otolaryngol Pol; 2011; 65(2):114-21. PubMed ID: 21735667
[TBL] [Abstract][Full Text] [Related]
39. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract][Full Text] [Related]
40. AlloDriver: a method for the identification and analysis of cancer driver targets.
Song K; Li Q; Gao W; Lu S; Shen Q; Liu X; Wu Y; Wang B; Lin H; Chen G; Zhang J
Nucleic Acids Res; 2019 Jul; 47(W1):W315-W321. PubMed ID: 31069394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
